跳至主要内容
临床试验/NCT07036068
NCT07036068尚未招募不适用

A Clinical Study on the Use of a Domestically Produced Cryoablation System Combined With Balloon Cryoablation Technology for the Treatment of Paroxysmal Atrial Fibrillation

Shanghai MicroPort EP MedTech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年8月31日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
20
试验地点
1
主要终点
Three-month follow-up success rate after surgery

研究概览

简要总结

To validate the safety and efficacy of balloon cryoablation technology and the accompanying disposable intracardiac mapping electrode catheter and adjustable guide sheath for the treatment of paroxysmal atrial fibrillation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient age between 18 and 80 years old, male or non-pregnant female.
  • Confirmed diagnosis of paroxysmal atrial fibrillation requiring cryoablation surgery.
  • Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.

排除标准

  • Patients who have undergone atrial fibrillation ablation surgery
  • Reproductive-age patients who cannot use effective contraception within 12 months of enrolment
  • Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%
  • Left atrial thrombus
  • Patients who have undergone atrial septal defect repair surgery or atrial myxoma
  • Patients with cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack)
  • Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision)
  • Patients with acute or severe systemic infection
  • Patients with severe liver or kidney disease
  • Patients with a significant tendency to bleed or haematological disorders
  • Patients with malignant tumours or end-stage diseases
  • Patients deemed ineligible for this trial by the investigator

结局指标

主要结局

Three-month follow-up success rate after surgery

时间窗: Three months after surgery

Postoperative 3-month treatment success rate: Specifically refers to the proportion of participants who, during the 3-month follow-up period post-surgery (after the washout period), did not experience any episodes of atrial fibrillation/atrial flutter/atrial tachycardia lasting ≥30 seconds, as confirmed by electrocardiogram (ECG), Holter monitoring, or equivalent rhythm monitoring methods (including single-lead ECG), without the use of Class I or Class III antiarrhythmic drugs, relative to the total number of enrolled participants.

次要结局

  • Immediate ablation success rate(On the 1 day of the surgery)

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Gao Henggan

Cui Kaijun

West China Hospital

研究点 (1)

Loading locations...

相似试验